Telix Precision Medicine
We are advancing molecular imaging designed to detect cancer with greater precision than conventional imaging, including hard-to-identify micrometastatic disease. By clearly revealing the location and extent of disease, these agents aim to support more confident diagnosis, treatment planning, and ongoing monitoring.
A powerful imaging modality
Our precision agents use targeting molecules labelled with radioisotopes to detect cancer via PET1 or SPECT2 scans.
These agents bind to specific proteins that are overexpressed on cancer cells or in the surrounding tumor environment, creating a signal that helps physicians locate and characterize disease.
Representative patient scan only
Where we’re making an impact
Our precision medicines focus on cancers where molecular imaging can inform clinical decision-making and help identify patients most likely to benefit from targeted therapy.
-
Prostate cancer
Prostate cancer is the most common male cancer worldwide, and a leading cause of cancer-related death.
Learn more
Our commercial imaging agents, Illuccix® and Gozellix® target PSMA, a protein highly expressed on the surface of prostate cancer cells, enabling detection that supports staging, and patient selection for radiopharmaceutical therapy.
-
Kidney cancer
Clear cell renal cell carcinoma (ccRCC) is the most common and among the most aggressive forms of kidney cancer.
Learn more
Our CAIX-targeted imaging candidate detects expression of this biomarker on tumor cells, offering a potential tool to identify disease and support more informed treatment strategies.
-
Brain cancer
Gliomas are the most common malignant primary brain tumors and are often complex to diagnose and stage.
Learn more
Our PET imaging candidate targets LAT1 (large amino acid transporter 1), helping distinguish recurrent or progressive disease from treatment-related changes and supporting more accurate clinical assessment. -
Blood cancer
Accurate assessment of bone marrow involvement is essential in hematologic cancers and prior to transplant.
Learn more
Our CD66-targeted imaging candidate allows precise visualisation of bone marrow activity, supporting better planning for bone marrow conditioning and treatment monitoring.
-
Bone cancer
Osteomyelitis, or bone infection, can be challenging to diagnose due to ambiguous symptoms, which can overlap with other conditions. Our CD66-targeted imaging agent, Scintimun®, supports more accurate localization of infection and offers an alternative to traditional white-blood-cell labelling.
Learn more
Prostate cancer is the most common male cancer worldwide, and a leading cause of cancer-related death.
Our commercial imaging agents, Illuccix® and Gozellix® target PSMA, a protein highly expressed on the surface of prostate cancer cells, enabling detection that supports staging, and patient selection for radiopharmaceutical therapy.
Clear cell renal cell carcinoma (ccRCC) is the most common and among the most aggressive forms of kidney cancer.
Our CAIX-targeted imaging candidate detects expression of this biomarker on tumor cells, offering a potential tool to identify disease and support more informed treatment strategies.
Gliomas are the most common malignant primary brain tumors and are often complex to diagnose and stage.
Our PET imaging candidate targets LAT1 (large amino acid transporter 1), helping distinguish recurrent or progressive disease from treatment-related changes and supporting more accurate clinical assessment.
Accurate assessment of bone marrow involvement is essential in hematologic cancers and prior to transplant.
Our CD66-targeted imaging candidate allows precise visualisation of bone marrow activity, supporting better planning for bone marrow conditioning and treatment monitoring.
Osteomyelitis, or bone infection, can be challenging to diagnose due to ambiguous symptoms, which can overlap with other conditions. Our CD66-targeted imaging agent, Scintimun®, supports more accurate localization of infection and offers an alternative to traditional white-blood-cell labelling.
Learn moreExplore clinical trials
Telix’s imaging candidates are studied in partnership with leading global cancer centres.
Precision medicine portfolio
7
FOOTNOTES
- PSMA – prostate-specific membrane antigen
- mCRPC – metastatic castration-resistant prostate cancer
- CAIX – carbonic anhydrase IX
- ccRCC – clear cell renal cell carcinoma
- LAT – L-type amino acid transporter
- CD66 – cluster of differentiation 66